SIETES :: 92916 citas

Resultados de la búsqueda por INVESTIGACIÓN REFINAR BÚSQUEDA

1.

Booth CM, Detsky AS. From the $80 hamburger to managing conflicts of interest with the pharmaceutical industry. BMJ 2019;365:3 de mayo. [Ref.ID 103106]

2.

Fuentes Camps I, Rodríguez A, Agustí A. Non-commercial vs. commercial clinical trials: a retrospective study of the applications submitted to a research ethics committee . Br J Clin Pharmacol 2018;84:junio. [Ref.ID 102808]

3.

Bally M, Dendukuri N, Rich B, Nadeau L, Helin-Salmivaara A, Garbe E, Brophy JM. Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data. BMJ 2017;357:j1909. [Ref.ID 101568]

4.

Saiz Fernández LC. Ensayo EMPA-REG OUTCOME (empagliflozina) El poder de la verdad, la verdad del poder.. Boletín de Información Farmacoterapéutica de Navarra 2016;24:1-13. [Ref.ID 101347]

5.

Solans-Domènech M, Permanyer-Miralda G. Evaluación del impacto de la investigación biomédica: ¿para quién?. Med Clin (Barc) 2016;146:491-3. [Ref.ID 100373]

6.

Townsley DM, Dumitriu B, Biancotto A, Weinstein B, Chen C, Hardy N, Mihalek AD, Lingala S, Kim YJ, Yao J, Jones E, Gochuico BR, Heller T, Wu CO, Calado RT, Scheinberg P, Young NS. Danazol treatment for telomere diseases. N Engl J Med 2016;374:1922-31. [Ref.ID 100340]

7.

Casassus B. France releases interim report on drug trial disaster. Lancet 2016;387:634-5. [Ref.ID 100049]

8.

Dyer O. US government is funding fewer trials as number of industry sponsored trials grows. BMJ 2015;351:h6893. [Ref.ID 99763]

9.

Naci H, Carter AW, Mossialos E. Why the drug development pipeline is not delivering better medicines. BMJ 2015;351:h5542. [Ref.ID 99639]

10.

McCarthy M. Industry paid $6.5bn to US physicians and hospitals in 2014. BMJ 2015;351:h3697. [Ref.ID 99244]

11.

Smith EMD, Foster HE, Beresford MW. The development and assessment of biological treatments for children. Br J Clin Pharmacol 2015;79:379-94. [Ref.ID 98956]

12.

Joseph PD, Craig JC, Caldwell PHY. Clinical trials in children. Br J Clin Pharmacol 2015;79:357-69. [Ref.ID 98955]

13.

Ferro A. Paediatric prescribing: why children are not small adults. Br J Clin Pharmacol 2015;79:351-3. [Ref.ID 98954]

14.

Kolata G. A faster way to try many drugs on many cancers. N Y Times (Print) 2015:25 de febrero. [Ref.ID 98846]

15.

Seife C. Research misconduct identified by the US Food and Drug Administration. Out of sight, out of mind, out of the peer-reviewed literature. JAMA Intern Med 2015;175:567-77. [Ref.ID 98774]

16.

Anónimo. Analysis: US share of funding for world’s biomedical research dropping. DIA Daily 2015:14 de enero. [Ref.ID 98723]

17.

Anónimo. The limitations and potential hazards of using surrogate markers . Therapeutics Initiative Evidence Based Drug Therapy 2014:octubre-diciembre. [Ref.ID 98447]

18.

Gulland A. WHO urges reporting of clinical trials within 18 months. BMJ 2014;349:g6292. [Ref.ID 98285]

19.

Anónimo. Familles de médicaments utilisés dans l'hépatite virale C. Prescrire 2014;34:762. [Ref.ID 98269]

20.

Anónimo. Corrélation entre réponse virologique prolongée et complications de l'hépatite C chronique. Prescrire 2014;34:760. [Ref.ID 98268]